HolderBook

Ghost Tree Capital, LLC

Reported holdings as of Q3 2024, from 25 quarterly filings.

This filer last reported in Q3 2024; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1595851
Reported value
$331.0M
Positions
52
Top 10 weight
42.4%
Filed
2024-11-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
SPDR SERIES TRUST PUTXBI$29.6Moptions only8.95%-newOPTIONS
BIOHAVEN LTD OPTBHVN$17.4M348,7785.26%-newNEW
SAREPTA THERAPEUTICS INCSRPT$15.0M120,0004.53%+1.81pp12q+118.2%+$8.1M
NOVO-NORDISK A SNVO$13.1M110,0003.96%-newNEW
BLUEPRINT MEDICINES CORPBPMC$12.9M140,0003.91%+2.56pp3q+250.0%+$9.2M
AXSOME THERAPEUTICS INCAXSM$12.1M135,0003.66%-0.12pp11q-10.0%-$1.3M
TARSUS PHARMACEUTICALS INCTARS$11.5M350,0003.48%+1.48pp14q+48.9%+$3.8M
PERSPECTIVE THERAPEUTICS INCCATX$10.0M750,0003.02%+0.14pp2q-18.9%-$2.3M
CG ONCOLOGY INCCGON$9.4M250,0002.85%+0.28pp3q-3.8%-$377.3K
ROIVANT SCIENCES LTDROIV$9.2M800,0002.79%-0.52pp6q-20.0%-$2.3M
VAXCYTE INCPCVX$9.1M80,0002.76%-0.79pp14q-46.7%-$8.0M
INSMED INC CALLINSM$9.1M75,0002.76%-2.80pp3q+15.4%+$1.2M
VIKING THERAPEUTICS INCVKTX$8.9M140,0002.68%+1.10pp3q+47.4%+$2.8M
SYNDAX PHARMACEUTICALS INCSNDX$8.7M450,0002.62%+0.37pp3q+28.6%+$1.9M
JANUX THERAPEUTICS INCJANX$8.6M190,0002.61%+1.95pp2q+280.0%+$6.4M
CORBUS PHARMACEUTICALS HLDGS PUTCRBP$7.8M160,0002.37%-0.11pp3q-8.6%-$734.9K
ASCENDIS PHARMA A/SASND$7.8M52,5002.37%-1.34pp2q-39.5%-$5.1M
CRINETICS PHARMACEUTICALS INCRNX$7.7M150,0002.32%-1.05pp5q-37.5%-$4.6M
SOLENO THERAPEUTICS INCSLNO$7.6M150,0002.29%-1.55pp4q-50.0%-$7.6M
TG THERAPEUTICS INCTGTX$7.3M310,0002.19%-0.60pp7q-38.0%-$4.4M
REZOLUTE INCRZLT$7.2M1,474,9952.16%+0.25pp2q+3.8%+$259.4K
PHATHOM PHARMACEUTICALS INCPHAT$6.8M375,0002.05%+0.11pp6q-37.5%-$4.1M
MOONLAKE IMMUNOTHERAPEUTICSMLTX$6.5M128,4111.96%-2.17pp7q-57.2%-$8.7M
OLEMA PHARMACEUTICALS INCOLMA$6.4M535,0001.93%+0.07pp3q-2.7%-$179.1K
IMMUNOVANT INCIMVT$6.1M215,0001.85%-0.30pp3q-17.3%-$1.3M
EDGEWISE THERAPEUTICS INCEWTX$5.2M195,0001.57%-newNEW
REPLIMUNE GROUP INCREPL$4.9M450,0001.49%+0.22pp6qHELD
BRIDGEBIO PHARMA INCBBIO$4.5M175,0001.35%+0.24pp7q+25.0%+$891.1K
TAYSHA GENE THERAPIES INCTSHA$4.3M2,150,0001.31%+0.43pp5q+72.0%+$1.8M
RHYTHM PHARMACEUTICALS INCRYTM$4.1M78,8421.25%-0.26pp3q-32.8%-$2.0M
ANNEXON INCANNX$3.8M650,0001.16%+0.36pp2q+109.7%+$2.0M
KORRO BIO INCKRRO$3.7M110,0001.11%+0.05pp2q+10.0%+$334.2K
DYNE THERAPEUTICS INCDYN$3.6M100,0001.09%-newNEW
ARVINAS INCARVN$3.6M145,0001.08%+0.45pp4q+93.3%+$1.7M
HELIX ACQUISITION CORP IIHLXB$3.1M300,0000.95%-0.01pp3qHELD
NUVATION BIO INCNUVB$3.1M1,350,0000.93%-0.12pp2q+17.4%+$458.0K
SAVARA INCSVRA$3.1M725,0000.93%-0.40pp4q-31.0%-$1.4M
TENAYA THERAPEUTICS INCTNYA$2.9M1,500,0000.87%-0.44pp3q+11.1%+$289.5K
REGENXBIO INCRGNX$2.8M265,0000.84%+0.22pp3q+55.9%+$996.5K
CORVUS PHARMACEUTICALS INCCRVS$2.6M500,0000.80%-newNEW
ABSCI CORPORATIONABSI$2.1M550,0000.63%-newNEW
NEUROGENE INCNGNE$2.1M50,0000.63%-0.16pp3q-28.6%-$839.2K
CAPRICOR THERAPEUTICS INCCAPR$1.9M125,0000.57%-newNEW
APELLIS PHARMACEUTICALS INCAPLS$1.9M65,0000.57%-1.06pp13q-51.9%-$2.0M
SUMMIT THERAPEUTICS INCSMMT$1.9M85,0000.56%-newNEW
SPYRE THERAPEUTICS INCSYRE$1.8M60,0000.53%-1.31pp3q-76.0%-$5.6M
VIRIDIAN THERAPEUTICS INCVRDN$1.7M75,0000.52%-1.88pp15q-87.2%-$11.7M
PROQR THRAPEUTICS N VPRQR$1.6M887,7000.49%+0.02pp2q-1.4%-$22.4K
ATYR PHARMA INCATYR$1.4M800,0000.43%+0.03pp3qHELD
LARIMAR THERAPEUTICS INCLRMR$1.3M200,0000.40%-newNEW
ENGENE HOLDINGS INCENGN$1.1M160,8980.32%-0.92pp3q-61.7%-$1.7M
AMYLYX PHARMACEUTICALS INCAMLX$1.1M325,0000.32%-newNEW

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 83.3%Not classified 16.7%
 
SectorValueShare
Biotech & Pharma$275.9M83.3%
Not classified$55.2M16.7%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q3 2024+12.9%+5.4%+7.4%90%
Q2 2024-9.8%+4.0%-13.8%91%
Q1 2024+9.8%+10.0%-0.2%84%
Q4 2023+22.2%+11.2%+11.0%77%
Q3 2023-21.0%-3.6%-17.4%97%
Q2 2023+9.8%+8.3%+1.5%82%
Q1 2023+11.5%+7.0%+4.5%100%
Q4 2022+10.6%+7.1%+3.5%83%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q3 2024$331.0M521116221942.4%45
Q2 2024$319.3M601122181943.5%45
Q1 2024$361.3M682924111041.0%45
Q4 2023$305.9M491313182759.3%45
Q3 2023$304.1M631813171248.1%45
Q2 2023$302.9M571524141252.1%45
Q1 2023$338.3M54261412751.1%45
Q4 2022$234.2M3586201157.9%45
Q3 2022$356.3M38121112560.6%45
Q2 2022$192.0M31510111559.4%46
Q1 2022$460.8M4178201175.2%46
Q4 2021$279.0M45918132247.9%47
Q3 2021$342.0M58188151143.0%46
Q2 2021$363.8M51159111349.2%42
Q1 2021$425.5M49161011949.0%133
Q4 2020$448.8M42139141752.2%49
Q3 2020$346.0M46161491258.1%47
Q2 2020$379.0M42910151449.3%45
Q1 2020$377.0M471410181663.2%45
Q4 2019$525.1M492013131354.8%100
Q3 2019$392.5M421210151256.4%192
Q2 2019$482.1M42147121062.3%284
Q1 2019$382.8M38111091055.3%375
Q4 2018$275.5M3788102261.1%465
Q3 2018$470.5M51000053.7%557

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.